Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease

Abstract

A placebo-controlled crossover design, with each treatment period lasting 6 weeks, was used to investigate effects of dronabinol in 15 patients with a diagnosis of probable Alzhemer's disease who were refusing food. Eleven patients completed both study periods; one patient who died of a heart attack 2 weeks before the end of the study was also included in the analysis. The study was terminated in 3 patients: one developed a grand mal seizure and 2 developed serious intercurrent infections. Body weight of study subjects increased more during the dronabinol treatment than during the placebo periods. Dronabinol treatment decreased severity of disturbed behavior and this effect persisted during the placebo period in patients who received dronabinol first. Adverse reactions observed more commonly during the dronabinol treatment than during placebo periods included euphoria, somnolence and tiredness, but did not require discontinuation of therapy. These results indicate that dronabinol is a promising novel therapeutic agent which may be useful not only for treatment of anorexia but also to improve disturbed behavior in patients with Alzheimer's disease.

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

“…The few clinical studies conducted so far have concentrated on specific symptoms, for example dementia-induced loss of appetite [102], but they have not investigated any disease-modifying effect. An interesting formulation to be investigated at the clinical level is the recently licensed phytocannabinoid-based medicine Sativex (GWPharma), which, based on the activity of its 2 components, Δ 9 -THC and CBD, at different complementary targets identified as neuroprotective in AD, e.g.…”

Sistema cannabinoide y regulación de la conducta alimentaria

“…En ensayos clínicos con agonistas cannabinoides en varias patologías se confirma este efecto orexíge-no, así aumentan el peso y el tejido graso en pacientes con SIDA (Abrams, Hilton, Leiser, Shade, Elbeik, Aweeka et al 2002), cáncer (Jatoi, Windschitl, Loprinzi, Sloan, Dakhil, Mailliard et al 2002) o enfermedad de Alzheimer (Volicer, Stelly, Morris, McLaughlin y Volicer, 1997).…”

O sistema endocanabinóide: nova perspectiva no controle de fatores de risco cardiometabólico

“…In our days, a considerable number of Cannabis Sativa analogues have been prescribed as antiemetic and appetite stimulants to oncology patients on chemotherapy. Dronabinol -a THC synthetic compound -was approved by the FDA over fifteen years ago as ancillary management for advanced stages of AIDS and cancer patients that develop anorexia and cachexia [22][23][24] .…”